Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
reAZURE-NAiVE ASIA: Phase 3 study of laroprovstat + rosuvastatin fixed-dose combination in lipid-lowering treatment-naive adults with primary hypercholesterolemia
CTR20263630Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of laroprovstat, rosuvastatin in hypercholesterolemia, familial hypercholesterolemia (FH), sponsored by AstraZeneca. Started Sep 2026; status: active.
02
Drugs
laroprovstatrosuvastatin
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on CTR20263630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263630.